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Abstract 
Background: Recent studies suggest that immunotherapy using T regulatory cells (Tregs) prolongs remission in type 
1 diabetes (T1DM). Here, we report factors that possibly affect the efficacy of this treatment.
Methods: The metabolic and immune background of 12 children with recently diagnosed T1DM, as well as that 
of untreated subjects, during a 2‑year follow‑up is presented. Patients were treated with up to 30 × 106/kg b.w. of 
autologous expanded CD3+CD4+CD25highCD127− Tregs.
Results: The disease progressed and all patients were insulin‑dependent 2 years after inclusion. The β‑cell function 
measured by c‑peptide levels and the use of insulin were the best preserved in patients treated with two doses of 
Tregs (3/6 in remission), less so after one dose (1/6 in remission) and the worst in untreated controls (no remissions). 
Increased levels of Tregs could be seen in peripheral blood after their adoptive transfer together with the shift from 
naïve CD62L+CD45RA+ to memory CD62L+CD45RA− Tregs. Increasing serum levels of proinflammatory cytokines 
were found: IL6 increased in all subjects, while IL1 and TNFα increased only in untreated group. Therapeutic Tregs 
were dependent on IL2, and their survival could be improved by other lymphocytes.
Conclusions: The disease progression was associated with changing proportions of naïve and memory Tregs and 
slowly increasing proinflammatory activity, which was only partially controlled by the administered Tregs. The thera‑
peutic cells were highly dependent on IL2. We conclude that the therapy should be administered at the earliest to 
protect the highest possible mass of islets and also to utilize the preserved content of Tregs in the earlier phases of 
T1DM.
Trial registration http://www.controlled‑trials.com/ISRCTN06128462; registered retrospectively
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Background
Type 1 diabetes (T1DM) is an emerging medical prob-
lem, since there is no causal treatment and patients inevi-
tably develop full onset of the disease, e.g., in Poland the 
consequent morbidity doubles every 10  years [1]. The 
majority of patients are children and the initial manifes-
tation can often be severe, including deep ketoacidosis 
or coma. It is, therefore, important to investigate novel 
treatments, aiming at early intervention, while a signifi-
cant mass of β-cells is still present and can be preserved.
A common consensus exists that the disease develops 
as a result of the attack of autoaggressive T-cells that 
infiltrate pancreatic islets and destroy insulin-producing 
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suppressive subsets, such as CD3+CD4+FoxP3+ T regu-
latory cells (Tregs), are somehow impaired [3]. Indeed, 
the adoptive transfer of Tregs was confirmed in animal 
models as an effective way to stop or delay the progres-
sion of the disease [4]. Translational studies in humans 
seem to confirm this observation, however, the disease 
still progresses in patients treated with Tregs preparation. 
It is, therefore, necessary to identify the factors that influ-
ence the efficacy of this therapy in the clinical setting.
Starting from 2009, therapy using T regulatory cells 
moved to the clinical stage and its efficacy is currently 
being assessed in various conditions, including T1DM 
[5]. Our group performed several such studies, includ-
ing that for the treatment of T1DM [5–8]. In this paper, 
apart from the clinical background, we will present some 
immunity studies in order to identify the factors that 




This was an open-labeled study conducted according to 
the Declaration of Helsinki principles and was approved 
by the Ethics Committee of the Medical University of 
Gdańsk, Poland (NKEBN/8/2010 with amendments). 
The trial was registered at the Current Controlled 
Trials database: http://www.controlled-trials.com/
ISRCTN06128462 (Additional file  1). Written informed 
consent was received from parents of all the participants 
and from the patients themselves, if above 16-years of 
age.
As described in earlier reports [7, 8], 12 Caucasian 
children from the Polish population with recently diag-
nosed T1DM were treated with ex vivo expanded autol-
ogous Tregs. The general health and metabolic status of 
the treated individuals were followed for 24 months after 
inclusion to the study along with those of ten untreated, 
control patients matched for age, sex and disease dura-
tion. The main inclusion criteria were: having autoim-
mune T1DM diagnosed within 2  months; the presence 
of at least one type of anti-islet autoantibody anti-GAD, 
anti-IA2, IAA, or ICA; age–5 to 18 years; fasting plasma 
C-peptide levels >0.4  ng/mL and proper management 
of diabetes. The control group was recruited among 
patients who fulfilled the same criteria, but did not qual-
ify for admission to the treated group due to inadequate 
venous access (Table 1).
Tregs were isolated from the patients’ peripheral blood 
with a GMP-compliant FACS sorter (Influx; BDBio-
sciences, USA). The purity of Tregs after sorting was 
≈98% (range 97–100%). The expansion was performed 
under GMP conditions and according to our previously 
described protocol using anti-CD3/anti-CD28 beads, 
interleukin 2 (IL-2) and autologous serum. The final 
product on release kept the FoxP3 expression above 90% 
[median (min.–max) = 91% (90–97)] [9].
The dose-escalation scheme of Tregs administration 
was: 10 × 106 of Tregs/kg b.w. in a single infusion (three 
patients), 20 ×  106 of Tregs/kg b.w. in a single infusion 
(three patients), and a total of 30 × 106 of Tregs/kg b.w. 
in two infusions (six patients), with the second dose 
being administered 6–9 months after the first one. Two 
patients were lost to follow-up at +6 and +9  months, 
while ten patients completed the trial.
The primary endpoints of the trial were safety and 
remission defined as daily dose of insulin (DDI) ≤0.5 UI/
kg b.w. and fasting C-peptide levels >0.5  ng/mL 1  year 
after recruitment. Secondary endpoints included the 
immune background of the patients treated with the 
preparation of Tregs.
Metabolic and immune responses
Fasting C-peptide levels, fasting glucose, HbA1c and 
T1DM autoantibody [glutamic acid decarboxylase 
autoantibody (anti-GAD65), insulin autoantibody (IAA), 
insulin antigen 2 antibody (IA2) and zinc transporter 8 
autoantibody (anti-ZnT8)] levels were measured during 
a 24-month-long follow-up at different time points, as 
previously described [7, 8]. The mixed meal tolerance test 
(MMTT) was performed according to standard criteria 
on the day of the 24th month of follow-up [10].
Immune phenotyping was performed using a seven-
color panel: CD3/CD4/CD25/CD127/CD45RA/
CD62L/FoxP3. Two phenotypes of Tregs were analyzed: 
CD3+CD4+FoxP3+ and CD3+CD4+CD25highCD127− 
T-cells. The gate CD25highCD127− from the later 
population was also used to assess the content 
of FoxP3+ T-cells in order to estimate an over-
lap between the two phenotypes of Tregs. Finally, 
CD3+CD4+FoxP3+ T-cells were subdivided into naive 
CD3+CD4+FoxP3+CD62L+CD45RA+ (Tn) Tregs, cen-
tral memory, CD3+CD4+FoxP3+CD62L+CD45RA− 
(Tcm) Tregs, and effector memory, 
CD3+CD4+FoxP3+CD62L−CD45RA− (Tem) Tregs [9].
The following anti-human monoclonal antibodies were 
used in this procedure (fluorochrome/class/clone): anti-
CD3 (PacificBlue/IgG1/UCHT1), anti-CD4 (PerCP/
IgG1/RPA-T4), anti-CD25 (PE/IgG1/M-A251), anti-
CD127 (FITC/IgG1/hIL-7R-M21) and, anti-CD45RA 
(PE-Cy7/IgG1/L48). All of the antibodies were purchased 
from BDBiosciences, Poland. Anti-CD62L (APC-Cy7/
IgG1/3B5) was supplied by Invitrogen, USA, and the 
FoxP3 staining kit by eBioscience, USA.
Serum levels of IFNγ, VEGF, TNFα, IL1, IL2, IL4, IL6, 
IL8, IL10 and, IL12 were measured with the Luminex 
Bead based Multiplex Assay (ebioscience, USA), while 
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BAFF, TGFβ, and, IL17 were measured with Quantikine 
High Sensitivity ELISA kit (R&D Systems, USA). All 
assays were performed according to the manufacturers’ 
instructions.
IL2 dependency tests
Samples of cells from Tregs expansions administered to 
the patients and autologous CD3+CD4+CD127+ conven-
tional/effector T-cells (Teffs) expanded along with Tregs 
were cultured for additional 8  days after the release of 
Treg products to the clinic. Tregs and Teffs were cultured 
separately or co-cultured in a 1:1 ratio, 1 × 106 cells/well 
in 24-well plates, in a 5% CO2 atmosphere, at 37.0 °C, in 
the following concentrations of IL2: 0.0, 10.0, 100.0 and 
1000 UI/mL. Survival of the cells was measured every day 
by flow cytometry using 7-aminoactinomycin D staining 
(7-AAD, Via-probe BDBiosciences, Poland).
Statistical analysis
Data were computed with the software Statistica 10.0 
(Statsoft, Poland). As indicated by the distribution of the 
variables non-parametric tests were used. The analysis 
was performed using Kruskal–Wallis ANOVA (KW), the 
U-Mann–Whitney test (MW), Wilcoxon test, and Spear-
man’s rank correlation. The p value was considered statis-
tically significant when <0.05 (Additional file 2).
Results
β‑cell function
β-cell function was best preserved in patients treated 
with two doses of Tregs, slightly less preserved in those 
treated with one dose and the least preserved in untreated 
controls. The criteria of remission were achieved at the 
24th month of follow-up in 3 out of 6 patients treated 
with two doses of Tregs, 1 out of 6 patients treated with 
a single dose of Tregs, while no remission occurred in the 
control group. There were no additional adverse effects, 
as compared to previous reports [7, 8].
As compared to untreated controls, the fasting C-pep-
tide level was significantly higher in individuals treated 
with a single or two doses of Tregs throughout the 
study (KW p < 0.05 on 4th and 12 month of follow-up). 
This difference between the single dose group and the 
untreated controls became insignificant at 2 years’ post-
recruitment (MW p = 0.43); however, it was still signifi-
cant when comparing the two dose and the untreated 
controls (MW p = 0.04) (Fig. 1).
A significant difference was also seen when daily 
insulin requirements were analyzed. When compared 
to untreated controls, both groups treated with Tregs 
required significantly lower doses of insulin through-
out the study (KW p < 0.05). The group treated with two 
Tregs doses required the lowest doses of exogenous insu-
lin, which maintained the levels of metabolic parameters, 
such as HbA1c and fasting glucose under control, notably 
at 2 years post inclusion (KW p < 0.05 at the 4th and the 
24 month of follow-up for fasting glucose). Importantly, 
two patients in the group treated with two doses were 
insulin independent more than 1 year after infusion.
The improved function of the islets in the groups 
treated with Tregs was also confirmed with mixed 
meal tolerance test (MMTT) at 2  years’ post-inclusion. 
Both treated groups were characterized by improved 
stimulated C-peptide profiles compared to those of 
the untreated group. The difference between the group 
treated with two doses and the untreated group was 
Table 1 Clinical characteristics of the patients
Treated (n = 12) Not treated (n = 10)
Age (years) [median; min–max] 12.2; 8–16 11.5; 7–16
BMI [median; min–max] 17.1; 12.5–23.5 16.7; 14.2–20.8
Polydipsia at diagnosis (number of patients) 5 8
Polyuria at diagnosis (number of patients) 5 3
Loss of weight at diagnosis (number of patients) 4 3
pH at diagnosis (capillary blood) [median; min–max] 7.40; 7.36–7.42 7.39; 7.35–7.53
pO2 at diagnosis (capillary blood—mmHg) [median; min–max] 69.3; 24.1–88.0 69.5; 56.0–86.6
pCO2 at diagnosis (capillary blood—mmHg) [median; min–max] 39.6; 28.0–46.9 38.0; 24.0–40.7
HCO3 at diagnosis (capillary blood—mmHg) [median; min–max] 24.15; 18.8–27.4 23.6; 21.3–25.2
Acid/base balance at diagnosis (BE—mEq/l) [median; min–max] 0.05; −7.8–3.2 −0.5; −3.8–0.9
Sat02 at diagnosis (capillary blood—%) [median; min–max] 94.1; 90.2–97.3 95.4; 92.4–97.2
Anti‑GAD65 antibody (number of patients) 9 9
ICA (number of patients) 7 5
IAA (number of patients) 7 4
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significant at all time points after the stimulation (KW 
p  <  0.05), whereas the difference between the group 
treated with one dose and the untreated group was insig-
nificant (KW p > 0.05) (Fig. 2).
Tregs levels in vivo
The level of Tregs increased each time the cells were 
administered (KW p  >  0.05) (Fig.  3a). Nevertheless, the 
increased level of Tregs was not sustained; it decreased 
to the baseline at 2  years after the first infusion (KW 
p  <  0.05). In addition, the increase in the level of Tregs 
after the second dose was not as high as after the first 
administration. Although there was a correlation 
between the percentages of the two phenotypes of Tregs 
CD3+CD4+FoxP3+ and CD3+CD4+CD25highCD127−, 
this was significant throughout the follow-up only in 
the group receiving two doses of Tregs (Fig.  3b, c). The 
analysis of FoxP3+ cells in the CD25highCD127− gate 
revealed that the percentage of FoxP3+ cells was signifi-
cantly decreasing in this gate in untreated patients and 
in those receiving a single dose of Tregs as T1DM pro-
gressed (Fig.  3b). On the other hand, there was no sig-
nificant decrease in the percentage of FoxP3+ cells in the 
CD3+CD4+CD25highCD127− gate in patients treated 
with two doses of Tregs. Among the three groups ana-
lyzed, this percentage was highest in the group treated 
with two doses of Tregs at the 24th month of follow-up 
(Kruskal–Wallis ANOVA χ2 = 6.66 p = 0.009).
Tregs subsets in vivo
The percentage of CD62L+CD45RA− Tcm Tregs 
increased after the administration of Tregs. There was 
Fig. 1 Metabolic markers of T1DM in studied groups. The fig‑
ure depicts levels of fasting C‑peptide (a), daily doses of insulin/
kg b.w. (DDI/kg) (b), levels of HbA1c (c) and fasting glucose (d) in 
T1DM children during the follow‑up: NO Tregs—untreated control 
group, single dose—patients treated with a single infusion, and two 
doses—patients treated with two infusions of Tregs. The following 
values of HbA1c in NGSP units (%) match the IFCC units (mmol/mol): 
3 = 9, 6 = 42, 9 = 75, 12 = 108, and 15 = 140. Data are presented as 
medians (min.–max.), while open circles represent particular patients. 
The significant differences in p values are shown in the figure: a com‑
parisons of C‑peptide levels in Kruskal–Wallis ANOVA between three 
groups at the 4th month (*) and 12 month (&) and Mann–Whitney U 
test comparison between the untreated group and the group treated 
with two doses of Tregs at the 24th month (#); b comparisons of daily 
doses of insulin in Kruskal–Wallis ANOVA between three groups at 
the 4th (*), 12 (&), and 24th month (#); c comparisons of hemoglobin 
A1c levels in Kruskal–Wallis ANOVA between three groups at day 0 
($) and the 12 month (&); d comparisons of fasting glucose levels in 
Kruskal–Wallis ANOVA between three groups at the 4th month (*) and 
24th month (#)
▸
Page 5 of 11Marek‑Trzonkowska et al. J Transl Med  (2016) 14:332 
a significant shift from the naïve CD62L+CD45RA+ Tn 
phenotype to the CD62L+CD45RA−, Tcm phenotype of 
Tregs immediately after the first infusion in both treated 
groups. (Wilcoxon test: first dose p < 0.05, second dose 
p > 0.05) (Fig. 4).
Immune markers of disease progression in peripheral 
blood
The control untreated group was characterized by a sig-
nificant shift of Treg subsets during the study (Fig.  4). 
Compared to the baseline, there was an increase in the 
level of Tcm Tregs at the expense of naïve Tregs at the 
24th month of follow-up. Similarly, but not as significant, 
changes were seen in patients treated with a single dose 
of Tregs. These differences were the least noticeable in 
the group treated with two doses of Tregs (Wilcoxon test: 
no Tregs p < 0.05, treated groups p > 0.05). Among the 
groups, the patients treated with two doses of Tregs pre-
served the proportions of Treg subsets at the 24th month, 
having the highest level of Tn Tregs and the lowest level 
of Tem Tregs (KW p < 0.05) (Fig. 4b).
Among the cytokines measured from sera, proinflam-
matory ones revealed some pattern during the follow-
up (Fig.  5). Serum levels of IL6 consistently increased 
with time, regardless of the therapy. All patients revealed 
higher levels of IL6 at the 24th month (Wilcoxon test, day 
0 vs. 24 month: p < 0.05). There was a slight and transient 
Fig. 2 Mixed meal tolerance test performed at the 24th month of 
follow‑up. Levels of C‑peptide in MMTT in T1DM children at the 24th 
month of follow‑up are displayed separately for untreated controls 
(NO tregs), patients treated with single infusion of Tregs (single 
dose) and patients treated with two infusions of Tregs (two doses). 
The values are given as medians (min.–max.) and the legend shows 
the timing of C‑peptide measurements in minutes during the test. 
The horizontal lines represent significant differences (p < 0.05) in 
C‑peptide levels in Kruskal–Wallis ANOVA between the untreated 
group and the group treated with two doses of Tregs in all ten time 
points of the test
Fig. 3 The levels of different phenotypes of Tregs and their correla‑
tion. a The percentage of Tregs measured as CD3+ CD4+ FoxP3+ 
cells during the follow‑up. The p values show the significance in 
Kruskal–Wallis ANOVA comparisons between three groups at day 
0 (*), 4th (&) and 12 month (#). b The percentage of FoxP3+ cells 
measured in the CD3+ CD4+ CD25highCD127− gate. The p values 
and the lines represent the significance of Wilcoxon test compari‑
sons: day 0 vs. 24th month in particular groups and **p represents 
the significance of Kruskal–Wallis ANOVA comparison between 
three groups at the 24th month. The values for untreated controls 
(NO Tregs), patients treated with a single infusion (single dose), and 
patients treated with two infusions (two doses) of Tregs are presented 
as medians (min.–max.); the open circles represent values from par‑
ticular patients. c Spearman’s rank correlation between CD3+ CD4+ 
FoxP3+ and CD3+ CD4+ CD25highCD127‑phenotypes used to 
assess the percentage of Tregs in the follow‑up (R and p are given for 
particular groups)
Page 6 of 11Marek‑Trzonkowska et al. J Transl Med  (2016) 14:332 
decrease immediately after the first dose only in the group 
administered with two doses of Tregs. Furthermore, the 
first infusion of Tregs in both treated groups was associated 
with a temporary decrease in the level of TNFα and IL1 
(Wilcoxon test: first dose p < 0.05, second dose p > 0.05).
In the control untreated group, the levels of TNFα, IL1, 
and IL6 were higher at the 12 month than at the start of 
the study (Wilcoxon test: p  <  0.05). Unfortunately, we 
have no data for these cytokines from the 24th month of 
follow-up. Apart from IL2, no significant changes were 
found in serum levels of other cytokines measured.
There was a correlation between the level of 
CD3+CD4+FoxP3+ Tregs in  vivo and IA2 (Spearman’s 
rank correlation R = −0.304, p = 0.05; Additional file 2: 
Figure S1). However, this was significant only when all 
groups were taken together in the analysis. No other 
T1DM autoantibodies (anti-GAD65, IAA, or anti-ZnT8) 
correlated with Treg levels, the dose of Tregs adminis-
tered, or the cytokines assessed (Fig. 6).
Tregs and IL2
In the first set of in vitro experiments, a sample of Tregs 
from the preparation used in the treatment was fur-
ther cultured with different concentrations of IL2, and 
cell survival was measured (Fig.  7a). While no supple-
mentation of IL2 was inevitably associated with a rapid 
decrease in cell survival, relatively low concentrations of 
IL2, starting from 10  UI/mL were enough to limit cell 
death (significant from the 2nd day of the culture, KW 
p < 0.05). IL2 should be present in the culture constantly, 
since a delayed application of the cytokine had only a 
minor effect on cell survival. In addition, simple co-cul-
ture of Tregs with Teffs without exogenous IL2 signifi-
cantly improved the viability (significant from 2nd day of 
the culture, KW p < 0.05). It was additionally synergized 
when exogenous IL2 was added to the co-cultures. Again, 
the effect was seen in co-cultures treated with different 
concentrations of IL2, from the lowest (10 UI/mL) up to 
the highest (KW p > 0.05 only at the 5th and 7th day).
Dependency of Tregs on IL2 found in  vitro was fur-
ther confirmed by the levels of this cytokine in the sera 
of patients. Shortly after Tregs infusions, notably in the 
Fig. 4 Subsets of tregs in the follow‑up. a The ratio between Tcm and 
Tn CD3+ CD4+ FoxP3+ Tregs is shown to better visualize the Tcm/Tn 
swap. b The percentages of Tn Tregs (upper panel), Tcm Tregs (middle 
panel), and Tem Tregs (bottom panel). The values for untreated controls 
(NO Tregs), patients treated with single infusion (single dose), and 
patients treated with two infusions (two doses) during the follow‑up. 
Data are presented as medians (min.–max.), and the open circles rep‑
resent particular patients. The *p values represent the significance in 
Kruskal–Wallis ANOVA comparisons between three groups at the 24th 
month; p values and short lines represent the significance of Wilcoxon 
test comparisons immediately after Tregs infusions in the treated 
groups; p values and long lines represent the significance of Wilcoxon 
test comparisons between day‑10 or day 0 vs. the 24th month in 
particular groups
▸
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group treated with two doses of Tregs, concentrations of 
IL2 transiently decreased, possibly due to the cytokine 
being metabolized by the infused Tregs (Wilcoxon test: 
first dose p > 0.05, second dose p < 0.05) (Fig. 7b).
Fig. 5 The levels of proinflammatory cytokines in the follow‑up. 
Serum concentrations of IL6 (upper panel) TNFα (middle panel) and IL1 
(bottom panel) were measured during the follow‑up. The values for 
untreated controls (NO Tregs), patients treated with a single infusion 
(single dose) and patients treated with two infusions (two doses) of 
Tregs are presented as medians (min.–max.), open circles represent 
values from particular patients. The p values and short lines represent 
the significance of Wilcoxon test comparisons immediately after 
Tregs infusions in treated groups; p values and long lines represent 
the significance of Wilcoxon’ test comparisons between day 0 vs. the 
12 month in the untreated group and day‑10 vs. the 24th month in 
treated groups
Fig. 6 T1DM autoantibodies in the follow‑up. The levels of anti‑
GAD65, IAA, IA2 and anti‑ZnT8 autoantibodies were measured. The 
values are shown for the untreated controls (NO Tregs), patients 
treated with single infusion (single dose) and patients treated with 
two infusions (two doses) during the follow‑up. Data are presented as 
medians (min.–max.), and the open circles represent particular patients
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Discussion
Cellular therapy with autologous expanded Tregs seemed 
to delay the progression of T1DM but its efficacy could 
be limited by several factors. As the treatment was intro-
duced after the initial onset of T1DM, probably only a 
small fraction of β-cells was still preserved in the body 
and could be protected from autoimmune attack, which 
was a major limitation of the success of the treatment. 
The advanced stage of the disease also affected the Tregs. 
The analysis of this population suggested that it was sub-
stantially evolving with the progression of the disease, 
and it was, therefore, beneficial to use autologous Tregs 
as early as possible in order to obtain an optimal prepa-
ration of Tregs for clinical applications. An additional 
dose of Tregs later in the study improved the results, but 
the effects were limited. The disease not only modified 
Tregs, but also the cytokine milieu towards stronger pro-
inflammatory activity, by increasing the levels of IL6 and, 
to a lesser extent, TNFα and, IL1. Finally, as confirmed 
in  vitro, survival of the expanded Tregs was dependent 
on IL2 and the interaction with other lymphocytes.
The time of recruitment to the treatment was an obvi-
ous medical limitation of the trial. Current diagnostics 
identify T1DM patients relatively late, when only 10–30% 
of the islets are still functional, so only this small frac-
tion can be spared from the disease [11]. Routine mark-
ers of autoimmunity in T1DM, such as autoantibodies, 
may identify patients in danger of disease development. 
However, their accuracy in prediction of the onset—nota-
bly when titers are low or some autoantibodies are not 
detectable yet—is not sufficient to identify early stage 
T1DM [12]. It is therefore imperative to develop credible 
criteria of imminent T1DM, ideally before clinical mani-
festation, while there is still a substantial mass of β-cells. 
An enrichment of the routine algorithm of T1DM diag-
nosis with HLA haplotyping, non-HLA polymorphisms, 
and an assessment of islet-autoreactive T-cells or circu-
lating DNA of the islets may allow the identification of 
patients in a very early stage of the disease [13–15]. The 
administration of Tregs to such patients would definitely 
improve the success of the therapy.
The need for early intervention is also justified by 
changes in the Treg population during T1DM progres-
sion. We have found that two phenotypes of Tregs, that 
is, CD3+CD4+FoxP3+ and CD3+CD4+CD25highCD127−, 
overlap, but diverge with time. It implies problems 
with acquiring Tregs for clinical expansion in the more 
advanced stage of the disease. It can be performed 
with either worse purity of putative Tregs or with pure 
Tregs at the expense of the number of sorted cells. In 
both cases, this can affect the quality of the prepara-
tion that is administered to the patient. Additional proof 
of the change in the population of Tregs in T1DM was 
a shifting proportion of naïve and memory Tregs as the 
disease progressed, notably in the untreated controls. 
In these subjects, there was a continuous shrinkage of 
the Tn compartment at the expense of more differenti-
ated memory subsets. Our previous studies suggested 
that inflammation associated with long-lasting T1DM 
was responsible for such an effect on Tregs. These cells 
were characterized by decreased expression of FoxP3 
and CD62L under proinflammatory conditions, and this 
effect could be reverted using anti-inflammatory agents 
[16–19]. It was intriguing that, in the current study, grad-
ual increase in the level of proinflammatory cytokines 
was seen early, starting from the clinical onset of T1DM. 
In addition, it was the only examined immune phenome-
non that could not be stopped completely by the adoptive 
transfer of Tregs.
Interestingly, a swap between naïve and memory Tregs 
could be also seen in interventional groups immediately 
after infusion of expanded Tregs. However, it would 
always revert to the baseline: 2  years after Tregs infu-
sion naïve and memory proportions were close to those 
observed at the beginning of the study. The patients 
administered with two doses of Tregs preserved propor-
tions closest to the baseline ratio. This temporary change 
was probably mostly caused by the content of the admin-
istered expanded Tregs, which are usually Tcm FoxP3high 
Tregs [9]. The fact that they reverted to the baseline ratio 
in treated subjects suggests a possibility that the level and 
proportions of Tregs, like other lymphocytes, are home-
ostatically regulated to some ‘baseline’ levels. Indeed, 
in our study, the Tcm/Tn proportion of Tregs reverted 
along with the numbers of total Tregs. Interestingly, 
the increase in the percentage of Tregs after infusions 
did not clearly correlate with the dose of administered 
Tregs, but with C-peptide levels, as shown in our previ-
ous report [8]. In addition, the increased level of Tregs, 
followed by higher C-peptide levels, could be seen after 
each infusion of the cells. Hence, the number of doses 
might be an independent factor affecting the efficacy of 
the treatment, equally important as the cumulative num-
ber of Tregs administered. If repetitive doses of Tregs can 
maintain an increased level of Tregs for a longer period, 
they can also maintain the C-peptide levels, which was 
observed in this study in patients treated with two doses 
of Tregs. The hypothesis on homeostatic regulation is 
therefore important for the treatment regimen, as split-
ting the therapy to repetitive smaller doses of Tregs could 
keep an increased level of Tregs in peripheral blood 
longer than a single high dose. The assumption on the 
Tregs homeostat should be completed with the effect of 
proinflammatory cytokines in T1DM. This proinflamma-
tory activity probably exerts significant influence, as seen 
in untreated controls, whose sera maintained high levels 
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of proinflammatory cytokines, as well as their Tregs pop-
ulations were shifted towards the memory subsets in a 
sustained way.
Finally, we assessed the effect of IL2 on expanded Tregs. 
This is the cytokine known to influence the survival and 
function of Tregs [20] and it was also used in high con-
centrations to expand Tregs for clinical application in this 
study. The production of the clinical preparation of Tregs 
required high doses of IL2 and its sudden deprivation on 
release of the product resulted in a fast decline in cell sur-
vival. Fortunately, there were two factors that probably 
protected Tregs viability in vivo. Even small doses of IL2 
added to cell culture—equal to the concentrations of IL2 
measured in sera of the patients—significantly improved 
Tregs viability. Furthermore, the addition of other lym-
phocytes, which probably secreted IL2 or supported 
Tregs through cell-to-cell interactions, improved Tregs 
viability. Most importantly, we found a synergic effect 
of IL2 and co-cultured Teffs on Tregs viability, since the 
survival of Tregs in co-cultures with Teffs and exogenous 
IL2 was comparable to the survival of other lymphocytes. 
In vivo, the concentration of IL2 decreased shortly after 
the infusion of Tregs in the group treated with two doses 
of Tregs, which might simply reflect an increased con-
sumption of IL2 by the infused Tregs. The dependence of 
Tregs on IL2 was tested in several clinical trials, in which 
IL2 was either given alone or administered together with 
expanded Tregs. The former has already been tested in 
T1DM, but appeared to be ineffective [21]. The latter was 
tested in graft-versus-host disease with some effect; how-
ever, although IL2 as a medicinal product is indicated 
Fig. 7 Tregs survival and dependency on IL2. a Survival of expanded 
Tregs was assessed in vitro after release from GMP laboratory for fur‑
ther 8 more days in various concentrations of IL2: 0.0, 10.0, 100.0 and 
1000 UI/mL. Tregs were cultured either alone (upper panel) or co‑cul‑
tured with CD4+ T effector cells (middle panel). The survival of CD4+ 
T effector cells cultured alone is presented for comparison (bottom 
panel). Results are presented as medians (min.–max.) of the percent‑
ages of 7‑AAD+ dead cells. Significant differences in Kruskal–Wallis 
ANOVA between cultures are shown: (*) Tregs without IL2 vs. Tregs 
with added IL2; (#) Tregs without IL2 vs. cocultures of Tregs and Teffs 
without IL2; ($) cocultures of Tregs and Teffs without IL2 vs. cocultures 
of Tregs and Teffs with IL2; (&) Tregs without IL2 vs. Teffs without IL2. b 
In vivo serum concentrations of IL2 were measured during the follow‑
up. The values for untreated controls (NO Tregs), patients treated with 
a single infusion (single dose) and patients treated with two infusions 
(two doses) of Tregs are presented as medians (min.–max.); the open 
circles represent values from particular patients. The p values and short 
line represents significance of Wilcoxon test comparisons immediately 
after the 2nd Tregs infusion
▸
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against tumors, the co-administration of IL2 and Tregs 
was associated with manifestation of malignancy [22]. 
Paradoxically, this might be the major threat of sys-
temic injections of IL2 with Tregs, since the exogenous 
cytokine might disturb trafficking of administered Tregs 
attracted to local inflammation, as in insulitis. It is an 
important argument as we confirmed that such an accu-
mulation of Tregs in human inflamed tissues exists [23]. 
Instead of chemotaxis towards inflamed tissues, Tregs 
injected in combination with exogenous IL2 may impose 
generalized systemic immunosuppression, facilitating 
progression of tumors. Hence, such combined interven-
tions should be performed with caution.
Conclusions
Currently, there are two centers that completed their 
first studies with Tregs in T1DM [7, 8, 24]. Safety was 
confirmed in both studies; however, the results are from 
small cohorts and, therefore, should be interpreted with 
caution. Still, the results can help design new, improved 
treatment protocols. As our trial included matched 
untreated controls, some efficacy could be also confirmed 
when comparing the data of the treated and untreated 
subjects. More importantly, we have found factors that 
most probably affect the efficacy of this therapy. Mainly, it 
is the advanced stage of the disease, which has a negative 
impact on the changes in the Tregs compartment. Based 
on our previous work, as well as this study, we assume 
that the inflammatory milieu characteristic for the pro-
gression of diabetes is responsible for these changes. 
High dependency of Tregs on IL2 may also influence the 
results, but this seems to be controlled by the IL2 pro-
duced in vivo. Early administration and repetitive doses 
of Tregs seemed to improve the results. Hence, new trials 
should take into account these observations in order to 
improve the efficacy of this approach. These factors were 
considered in the design of our new currently ongoing 
trial TregVac2.0 registered as EudraCT: 2014-004319-
35 [5], in which two doses of Tregs are administered in 
a 3-month interval, and patients are recruited in earlier 
phases of the disease.
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